Quadruplet therapy for newly diagnosed myeloma: comparative analysis of sequential cohorts with triplet therapy lenalidomide, bortezomib and dexamethasone (RVd) versus daratumamab with RVD (DRVd) in transplant-eligible patients

2024-9-13

Comparative effectiveness of 6x R-CHOP21 versus 6x R-CHOP21 + 2 R for patients with advanced-stage diffuse large B-cell lymphoma

2024-9-12

Bispecific antibodies in the treatment of multiple myeloma

2024-9-12

Belantamab mafodotin, pomalidomide, and dexamethasone for triple class exposed/refractory relapsed multiple myeloma: a subgroup analysis of the ALGONQUIN trial

2024-9-11

Association of ADAM family members with proliferation signaling and disease progression in multiple myeloma

2024-9-11

Global, regional, and national burden of Burkitt lymphoma from 1990 to 2021 and predictions to 2030: a systematic analysis for the Global Burden of Disease Study 2021

2024-9-9

Blood neurofilament light chain measurements in adults with CNS histiocytic neoplasms

2024-9-5

Phase II trial of elotuzumab with pomalidomide and dexamethasone for daratumumab-refractory multiple myeloma

2024-9-5

Increased risk of subsequent neoplasm after hematopoietic stem cell transplantation in 5-year survivors of childhood acute lymphoblastic leukemia

2024-8-28

Genome profiling with targeted adaptive sampling long-read sequencing for pediatric leukemia

2024-8-28

B-cell intrinsic RANK signaling cooperates with TCL1 to induce lineage-dependent B-cell transformation

2024-8-28

Disparities in relapsed or refractory multiple myeloma: recommendations from an interprofessional consensus panel

2024-8-27

Multi-omics profiling of longitudinal samples reveals early genomic changes in follicular lymphoma

2024-8-27

Longitudinal assessment of established risk stratification models in patients with monoclonal gammopathy of undetermined significance

2024-8-27

Del(1p32) is an early and high-risk event in multiple myeloma patients with extraosseous disease

2024-8-26

Safety and efficacy of blinatumomab as bridge-to-transplant for B-cell acute lymphoblastic leukemia in first complete remission with no detectable minimal residual disease

2024-8-23

Venetoclax with hypomethylating agents versus intensive chemotherapy in newly diagnosed acute myeloid leukemia with myelodysplasia related changes: A propensity score-matched analysis based on International Consensus Classification

2024-8-23

Disparities in time to treatment with oral antimyeloma medications

2024-8-23

Busulfan-fludarabine versus busulfan-cyclophosphamide for allogeneic transplant in acute myeloid leukemia: long term analysis of GITMO AML-R2 trial

2024-8-21

Survival of patients with classical Hodgkin lymphoma in Finland: a national population-based analysis

2024-8-20

Haplotype analysis identifies functional elements in monoclonal gammopathy of unknown significance

2024-8-20

Dual therapeutic targeting of MYC and JUNB transcriptional programs for enhanced anti-myeloma activity

2024-8-19

Sustained remission following finite duration bispecific antibody therapy in patients with relapsed/refractory myeloma

2024-8-12

A roadmap towards improving outcomes in multiple myeloma

2024-8-12

Chimeric antigen receptor T-cell therapy associated hemophagocytic lymphohistiocytosis syndrome: clinical presentation, outcomes, and management

2024-8-12

Progression-free survival as a surrogate endpoint in myeloma clinical trials: an evolving paradigm

2024-8-12

Liver elastography for risk-assessment of liver toxicity and risk factors for Sinusoidal obstruction syndrome in patients with acute lymphoblastic leukemia receiving inotuzumab ozogamicin

2024-8-7

Identification of genetic subtypes in follicular lymphoma

2024-8-7

Flow cytometric analysis of erythroid precursors and mutational signatures of lower risk myelodysplastic syndromes identify responders to erythroid stimulating agents

2024-8-7

Bispecific CAR-T cells targeting CD19/20 in patients with relapsed or refractory B cell non-Hodgkin lymphoma: a phase I/II trial

2024-8-7

Serum levels of B-cell activating factor are associated with a reduced risk of chronic lymphocytic leukemia

2024-8-7

Dynamics of microcyst-like epithelial changes associated with Belantamab mafodotin therapy in a patient with multiple myeloma—a case report

2024-8-7

Measurable residual disease (MRD) dynamics in multiple myeloma and the influence of clonal diversity analyzed by artificial intelligence

2024-8-7

Real-life sensitivity of flow cytometry minimal residual disease assessment for plasma cell neoplasms

2024-7-31

Non-canonical FLT3 alterations reveal novel germline FLT3 variants leading to somatic gene rescue mutations

2024-7-30

IgG replacement in multiple myeloma

2024-7-25

Correction: Anti-CD5 CAR-T cells with a tEGFR safety switch exhibit potent toxicity control

2024-7-24

Clinical features associated with poor response and early relapse following BCMA-directed therapies in multiple myeloma

2024-7-23

Risk factors in DUX4-positive childhood and adolescent B-cell acute lymphoblastic leukemia

2024-7-22

Co-mutation landscape and its prognostic impact on newly diagnosed adult patients with NPM1-mutated de novo acute myeloid leukemia

2024-7-22

Racial disparities in multiple myeloma and access to stem cell transplantation

2024-7-22

Prevalence and distribution of M-proteins in the oncologic population affected by solid tumor

2024-7-22

Genomic and immune determinants of resistance to daratumumab-based therapy in relapsed refractory multiple myeloma

2024-7-19

Myeloid neoplasms arising after methotrexate therapy for autoimmune rheumatological diseases do not exhibit poor-risk molecular features

2024-7-19

Long term responders in frontline multiple myeloma—exception vs expectation of the modern era

2024-7-17

Using Mendelian Randomisation to search for modifiable risk factors influencing the development of clonal haematopoiesis

2024-7-16

Improved prevention and treatment strategies for differentiation syndrome contribute to reducing early mortality in patients with acute promyelocytic leukemia

2024-7-15

Prognostic and therapeutic implications of TP53 expression in chronic myelomonocytic leukemia

2024-7-12

Immune dysfunction prior to and during vaccination in multiple myeloma: a case study based on COVID-19

2024-7-10

Efficacy of blinatumomab as maintenance therapy for B-lineage acute lymphoblastic leukemia/lymphoma following allogeneic hematopoietic cell transplantation

2024-7-8